1[1]Weber JL,Dagmar K,Kalouse K,et al.Placental mossaicism and intrauterine survivival of trisomies 13 and 18[J].Am J hum Genet,1989,44:338.
2[2]Thibodeau SN,Bren G,Schaid D.Microsatellite instability in cancer of the proximal colon[J].Science,1993,260:816.
3[3]Aaltonen LA,Lauri A,Leach,et al.Clues to the pathogenesis of familial colorectal cancer[J].Science,1993,260:812.
4[4]Ionov Y,Miguel A,Peinado,et al.Ubiquitous somatic mutations in simple repeated sequences reveal a new echanism for colon carcinogeesis[J].Nature,1993,363:558.
5[5]Boyer JC,Umar A,Risinger JI,et al.Microsatellite instability mismatch repair beficiency and genetic defect in human cancer cell lines[J].Cancer Res,1995,(24):6063-6070.
6[6]Risinger JI,Umar A,Boyer JC,et al.Microsatellite instabillty in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity[J].Cancer Res,1995,55(23):5664-5669.
7[7]Keller G,Rudelius M,Vogelsang H,et al.Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparion to family history[J].Cancer Res,1998,58:192.
8[8]Lothe RA,Ragnhild A,Lauri A,et al.Genomice instability in colorectal cancor:Rclationship to clinicopathological variables and family history[J].Cancer Res,1993,53:5849.
9[9]Zhou XP,Hoang JM,Li YJ,et al.Determination of the replication error phenotype in human tumors withour the requriement for mating normal DNA by analysis of mononucleotide repeat microsatellites[J].Genes Chromosome Cancer,1998;21(2):101-107.
10[10]Zhou XP,Hoang JM,Cottup,et al.Allelic profiles of monoucleotide repeat microsatellites in control individuasl and in colorectal tumors with and without replicatoin errors[J].Cancer,1997,15(14):1713-1718.
3Weitz J,Koch M,Debus J. Colorectal cancer[J].The Lancet,2005,(9454):153-165.doi:10.1016/S0140-6736(05)17706-X.
4Lievre A,Bachet JB,Le Corre D. K-Ras mutation status is predictive of response to cetuximab therapy in colorectal cancer[J].Cancer Research,2006,(08):3992-3995.
5Khamvata-Ford S,Garrett CR,Meropol NJ. Expression of epiregulin and amphiregulin and K-Ras mutation status predict disease control in metastatic colorectal Cancer patients treated with cetuximab[J].Journal of Clinical Oncology,2007,(22):3230-3237.
6Jonker DJ,O'Callaghan C J,Karapetis CS. Cetuximab for the treatment of colorectal cancer[J].New England Journal of Medicine,2007,(20):2040-2048.
7Van Cutseme,Lang I,Dhaens G. K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetux-imab:the CRYTAL experience[J].Journal of Clinical Oncology,2008,(Supp1):a2.
8Paliga A,Onerheim R,Gologan A. EGFR and K-ras gene mutation status in squamous cell anal carcinoma:a role for concurrent radiation and EGFR inhibitors[J].British Journal of Cancer,2012,(11):1864-1868.
9Goldstein NS,Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage Ⅳ colon adenocarcinoma[J].Cancer,2001,(05):1331-1346.
10Spano JP,Lagorce C,Atlan D. Impact of EGFR expression on colorectal cancer patient prognosis and survival[J].Annals of Oncology,2005,(09):102-108.
